Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.47 |
| ▸ | CCR5 | P51681 | 1/20 | 0.47 |
| ▸ | CCR8 | P51685 | 1/20 | 0.47 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.45 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | ERN1 | O75460 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31207190 | 1.00 | CCR1 (0.47) | CCR1CCR5CCR8TRIM24TRIM33 | |
| SCHEMBL31329733 | 0.81 | ALDH1A1 (0.35) | CCR1CCR5CCR8TRIM24TRIM33 | |
| SCHEMBL27887406 | 0.80 | TRIM24 (0.57) | CCR1CCR5CCR8TRIM24TRIM33 | |
| SCHEMBL748190 | 0.77 | CCR1 (0.50) | CCR1CCR5CCR8TRIM24TRIM33 | |
| SCHEMBL30529332 | 0.77 | CCR1 (0.50) | CCR1CCR5CCR8TRIM24TRIM33 | |
| SCHEMBL26427204 | 0.77 | CCR1 (0.45) | CCR1CCR5CCR8TRIM24TRIM33 | |
| SCHEMBL28868517 | 0.77 | TRIM24 (0.53) | CCR1CCR5CCR8TRIM24TRIM33 | |
| SCHEMBL31130636 | 0.77 | CCR1 (0.45) | CCR1CCR5CCR8TRIM24TRIM33 | |
| SCHEMBL13257417 | 0.74 | CCR1 (0.47) | CCR1CCR5CCR8TRIM24TRIM33 | |
| SCHEMBL1637824 | 0.74 | CCR1 (0.47) | CCR1CCR5CCR8TRIM24TRIM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383915-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2024-11-21 | — | — | US | disclosed |
| WO-2024168004-A1 | BIARYL AMIDE-CONTAINING AGONISTS OF OREXIN RECEPTOR TYPE 2 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-08-15 | — | — | WO | disclosed |
| EP-4320132-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| CN-117083279-A | Oxazepine compounds and their use in the treatment of cancer | 基因泰克公司 | 2023-11-17 | — | — | CN | disclosed |
| WO-2022216762-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2022040157-A1 | BORON CONTAINING COMPOUNDS AND THEIR USES | 5METIS, INC. (US) | 2022-02-24 | — | — | WO | disclosed |
| CN-106999479-A | It can be used as the heteroaryl compound of SUMO activating enzyme inhibitors | 米伦纽姆医药公司 | 2017-08-01 | — | — | CN | disclosed |
| CN-105189476-B | Pyrazole derivatives | 帝人制药株式会社 | 2017-07-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383915-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | OXA1L, GRIK4, GRIK5 | CCR1 3941/4885CCR5 2823/4885CCR8 4302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.